Email this article Novel and Latest Computational Routes in the Design and Development of Anticancer Drugs
- Authors: Kamal M.1, Akhtar S.2
-
Affiliations:
- Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, Sichuan University
- Department of Bioengineering, Faculty of Engineering & Information Technology,, Integral University,
- Issue: Vol 31, No 5 (2024)
- Pages: 552-553
- Section: Anti-Infectives and Infectious Diseases
- URL: https://clinpractice.ru/0929-8673/article/view/645162
- DOI: https://doi.org/10.2174/092986733105230911112507
- ID: 645162
Cite item
Full Text
About the authors
Mohammad Kamal
Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, Sichuan University
Email: info@benthamscience.net
Salman Akhtar
Department of Bioengineering, Faculty of Engineering & Information Technology,, Integral University,
Email: info@benthamscience.net
References
- Talluri, S.; Kamal, M.A.; Malla, R.R. Novel computational methods for cancer drug design. Curr. Med. Chem., 2024, 31(5), 554-572.
- Ghosh, A.; Ghosh, D.; Mukerjee, N. et al. The efficient activity of glabridin and its derivatives against EGFR-mediated inhibition of breast cancer. Curr. Med. Chem., 2024, 31(5), 573-594.
- Shah, A.A.; Ahmad, S.; Yadav, M.K.; Raza, K.; Kamal, M.A.; Akhtar, S. Structure-based virtual screening, molecular docking, molecular dynamics simulation, and metabolic reactivity studies of quinazoline derivatives for their anti-EGFR activity against tumor angiogenesis. Curr. Med. Chem., 2024, 31(5), 595-619.
- Alam, S.; Verma, S.; Fatima, K.; Luqman, S.; Srivastava, S.K.; Khan, F. Pharmacophore & QSAR guided design, synthesis, pharmacokinetics, and in vitro evaluation of curcumin analogs for anticancer activity. Curr. Med. Chem., 2024, 31(5), 620-639.
- Ahmad, S. lshammari, Q.T.; Rafi, Z. et al. Generation of autoantibodies in metal-catalyzed oxidatively damaged DNA in various cancer subjects. Curr. Med. Chem., 2024, 31(5), 640-648.
- Mirza, Z. Integrated high-throughput transcriptomic data identifies survivin as a potential breast cancer therapeutic biomarker. Curr. Med. Chem., 2024, 31(5), 649-663.
Supplementary files
